Regen BioPharma, Inc.
RGBP
$0.01
$0.0020.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.51% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.51% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.51% | 0.00% | |||
| SG&A Expenses | 71.04% | -42.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 82.77% | -42.11% | |||
| Operating Income | -201.72% | 63.99% | |||
| Income Before Tax | -242.20% | -762.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -242.20% | -762.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -242.20% | -762.37% | |||
| EBIT | -201.72% | 63.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -147.14% | -677.78% | |||
| Normalized Basic EPS | -145.45% | -633.33% | |||
| EPS Diluted | -147.14% | -677.78% | |||
| Normalized Diluted EPS | -145.45% | -633.33% | |||
| Average Basic Shares Outstanding | 39.02% | 10.20% | |||
| Average Diluted Shares Outstanding | 39.02% | 10.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||